FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

RedHill’s Experimental MS Therapy, RHB-104, Receives Notice of Allowance on U.S. Patent




























RedHill Biopharma, Ltd., an Israeli biopharmaceutical company focused on the development and commercialization of oral-administered small-molecule medicines for the treatment of inflammatory and gastrointestinal diseases, recently announced it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent covering its product RHB-104. This drug was originally developed for the treatment of Crohn’s disease, but is now being pursued as a complementary therapy for relapsing remitting multiple sclerosis (RRMS) due to its potential anti-inflammatory and neuroprotective properties.

RHB-104 consists of an oral capsule formulation of an antibiotic combination therapy — 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine — with strong intracellular, anti-mycobacterial and anti-inflammatory properties. If the U.S. patent application, titled “Compositions Comprising Rifabutin, Clarithromycin, and Clofazamine and Uses Therof,” is granted, it will cover methods of use of RHB-104 and will be valid until 2029.

Currently, RHB-104 is undergoing a Phase 3 clinical trial for the treatment of Crohn’s disease in a number of countries, including the U.S., Canada, Israel, and Australia (the MAP US study). Moreover, the drug is also undergoing a proof-of-concept, Phase 2a clinical trial that has 18 patients enrolled, with the objective to evaluate RHB-104 efficacy as an adjuvant therapy to treatment with interferon beta-1a in patients with RRMS. The CEASE-MS study, titled “Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis,” is expected to yield its first results in the upcoming weeks.

RedHill Biopharma is also developing clinical candidate drugs to treat infection with Helicobacter pylori, acute gastroenteritis and gastritis, gastrointestinal cancers, pancreatic cancer, other solid tumors, and acute migraines. If the current patent is approved, RedHill will hold five U.S. patents for RHB-104 and other international ones.

Dr. Danielle Abramson, RedHill’s director of Intellectual Property & Research, said in a press release, “We are very pleased to announce this new addition to RedHill’s already robust patent portfolio covering RHB-104. The Phase III study with RHB-104 for Crohn’s disease, currently ongoing in the U.S. and additional countries, is advancing well, with interim analysis expected in the second half of 2016.”

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length 
Click here to read original article


Go to Newer News Go to Older News